<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919253</url>
  </required_header>
  <id_info>
    <org_study_id>HBBL-01</org_study_id>
    <nct_id>NCT03919253</nct_id>
  </id_info>
  <brief_title>Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study</brief_title>
  <official_title>Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aim to evaluate the efficacy and safety of Pyrotinib in combination with
      nab-paclitaxel in patients with HER2-positive advanced breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival(PFS)</measure>
    <time_frame>three years</time_frame>
    <description>Baseline to measured date of progress or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>three years</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>three years</time_frame>
    <description>The percentage of subjects with Complete Response, Partial Response, or Stable Disease at least 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>three years</time_frame>
    <description>Rate of the patients with disease control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to death</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (number of Participants with adverse events)</measure>
    <time_frame>three years</time_frame>
    <description>Adverse events Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. The number of Participants with adverse events will be recorded at each treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>pyrotinib maleate tablets+nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pyrotinib maleate tablets: 400mg orally once daily continunously; nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>pyrotinib maleate tablets+nab-paclitaxel</intervention_name>
    <description>pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.</description>
    <arm_group_label>pyrotinib maleate tablets+nab-paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age: 18-70 years old，female; 2. Pathologically confirmed HER2-positive invasive
             breast cancer by local laboratory with the following requirements: HER2 overexpressed
             or amplified (immunohistochemistry of 3+ or HER2 gene amplification by in situ
             hybridization) 3. Imaging examination confirmed recurrent/metastatic breast cancer； 4.
             Patients must have previous treatment with trastuzumab more than 9 weeks; 5. Untreated
             for metastatic/metastatic disease (except for endocrinotherapy); 6. Patients with at
             least one measurable lesions by RECIST version 1.1； 7. Eastern Cooperative Oncology
             Group (ECOG) performance status 0-2； 8. Life expectancy greater than or equal to 3
             months; 9. Participants must have normal organ and marrow function as described below：
             Absolute neutrophil count≥1.5×109/L; Platelets≥90×109/L; Hemoglobin ≥90g/L； Total
             bilirubin ≤ 1.5 X institutional upper limit of normal (ULN)； ALT and AST≤2*ULN, but
             ≤5*ULN with liver metastases; BUN and Cr≤1.5×ULN or creatinine clearance ≥50ml/min
             Left ventricular ejection fraction (LVEF) ≥ 50% 10. Doctors believe that treatment can
             bring benefits to patients； 11. Participants were willing to join in this study, and
             written informed consent.

        Exclusion Criteria:

          -  1. A variety of factors influencing oral drugs (after resection of the
             gastrointestinal, unable to swallow, Chronic diarrhea, intestinal obstruction); 2.
             Patients with other malignant tumors within 5 years (except for skin basal cell
             carcinoma and cervical carcinoma in situ); 3. History of psychiatric drugs abuse or
             patients with mental disorders; 4. Pregnant or lactating women; 5. Less than 4 weeks
             from the last clinical trial 6. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

